The Alarming Rise of Medicalisation in India Amidst Obesity Epidemic
India faces a growing obesity epidemic and associated metabolic conditions, leading to an alarming rise in medicalisation. The market for anti-obesity drugs is expanding rapidly, with new medications like semaglutide and tirzepatide gaining prominence. However, concerns are rising about aggressive marketing, potential side effects like sarcopenia (muscle loss), and a 'cascading logic' where drugs for one condition lead to more drugs for side effects. Experts highlight the limited attention given to fundamental drivers like ultra-processed foods and call for a shift towards lifestyle modifications and ethical medical practices, rather than solely relying on pharmacological solutions.
Key Points
- India is experiencing a significant increase in obesity and related metabolic conditions, driving a trend of medicalisation.
- The market for anti-obesity drugs is rapidly expanding, with new medications becoming widely available.
- Concerns exist regarding the aggressive marketing of these drugs and their potential side effects, such as sarcopenia.
- There is a call for a paradigm shift to address the root causes of obesity, like ultra-processed foods, and prioritize lifestyle changes over solely pharmacological interventions.
- The influence of pharmaceutical companies on clinical guidelines and public perception is a growing concern.
Exam Facts
- Nearly a quarter of Indians are overweight or obese; one in ten adults has diabetes.
- Anti-obesity drugs like semaglutide and tirzepatide are mentioned.
- Sarcopenia, the loss of lean muscle mass, is a noted side effect of some anti-obesity medications.
- The ultra-processed food sector in India grew by 13% between 2011 and 2021.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.